27 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Mechanisms of Evasive Resistance in Cancer (MERiC)
Date du début: 1 mai 2014, Date de fin: 30 avr. 2020,
Cancer is a major health problem due to the failure of current therapies to effectively eradicate the disease. Alternative signaling pathways compensate for a therapeutically targeted pathway, a process referred to as 'evasive resistance'. The identities of the alternative signaling pathways and functional interconnections that underlie evasive resistance remain widely unknown. We propose to integ ...
Voir le projet
3
Participants partenaires
TERMINÉ
Imaging the Force of Cancer (FORCE)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet
18
Participants partenaires
TERMINÉ
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,
ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Voir le projet
7
Participants partenaires
TERMINÉ
Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,
Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptabl ...
Voir le projet
17
Participants partenaires
TERMINÉ
Training scientists to develop and Image materials for Tissue Engineering and Regenerative Medicine (iTERM)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
The iTERM ITN (4 companies, 6 universities) will deliver 12 early stage researchers (ESR) and 1 experienced researcher (ER) trained in imaging, material science, and tissue engineering & regenerative medicine (TERM). For the aging population in the EU donor material is often not available, and artificial tissue needs to be developed to replace and repair damaged tissues. New smart materials have b ...
Voir le projet
8
Participants partenaires
TERMINÉ
Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope (EU-CERT-ICD)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have dramatically increased in recent years leading to multi-billion Euros of costs with significant regional disparities across Europe. Information on risks, benefits and cos ...
Voir le projet
27
Participants partenaires
TERMINÉ
VitaminD3-Omega3-Home Exercise- HeALTHy Ageing and Longevity Trial (DO-HEALTH)
Date du début: 1 janv. 2012, Date de fin: 30 juin 2017,
As the European population is ageing rapidly, the growing number of seniors with age-related chronic diseases poses a challenge on European societies and health care systems. Therapeutic interventions that are effective, affordable and well-tolerated in the prevention of chronic disease are urgently needed and will have an outstanding impact on public health as a whole. Among the most promising in ...
Voir le projet
25
Participants partenaires
TERMINÉ
Development of Biomaterial-based Delivery Systems for Ischemic Conditions - An Integrated Pan-European Approach (AngioMatTrain)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,
AngioMatTrain focuses on the comprehensive, multidisciplinary understanding of ischemic diseases, from basics to translation, fully supported by 8 full partners (5 universities, 1 hospital and 2 SMEs). This ITN will educate and train 12 Early Stage Researchers and 3 Experienced Researchers scientists in: tissue engineering, materials science, chemistry, functionalisation, cell biology, nanotechnol ...
Voir le projet
8
Participants partenaires
TERMINÉ
Decision-making within cells and differentiation entity therapies (DECIDE)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiat ...
Voir le projet
8
Participants partenaires
TERMINÉ
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet
39
Participants partenaires
TERMINÉ
Health Care Work Exchange 2014
Date du début: 1 juin 2014, Date de fin: 31 mai 2016,
...ect that meets students’ needs for high-quality and technically challenging internships abroad. In addition, more than 100 partner organizations throughout Europe participate in this project. University teaching hospitals, private medical practices, rehabilitation centers, public and private hospitals and clinics offer internships and a variety of educational institutions assist as intermediary pa ...
Voir le projet
27
Participants partenaires
TERMINÉ
Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)
Date du début: 1 oct. 2011, Date de fin: 31 mars 2016,
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.Based on harmonised and standardised European population cohorts we have built significant research collabo ...
Voir le projet
31
Participants partenaires
TERMINÉ
Bioreactor-based, clinically oriented manufacturing of engineered tissues (BIO-COMET)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2015,
Despite significant achievements in the field of regenerative medicine and the enormous potential for engineered tissue products, significant hurdles have prevented cellular therapies from gaining wide-spread clinical adoption. Manufacturing related issues have been proposed as key challenges to be addressed for the translation of regenerative therapies to the clinic and the successful commerciali ...
Voir le projet
9
Participants partenaires
TERMINÉ
Combined Highly Active Anti-retroviral Microbicides (CHAARM)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Voir le projet
34
Participants partenaires
TERMINÉ
T cell receptor αβ : in control of signal initiation and T cell fate (TERRAINCOGNITA)
Date du début: 1 avr. 2010, Date de fin: 31 mars 2015,
One of the central mysteries of immunology is self-tolerance. How does the human body select ~10e12 T lymphocytes, that are reactive to foreign pathogens but tolerant to normal cellular constituents of the host? Over the last few years, my laboratory identified 2 fundamental mechanisms used by thymocytes to establish T cell tolerance. We demonstrated that the affinity threshold for negative select ...
Voir le projet
1
Participant partenaire
TERMINÉ
COMPOSITE PHENOTYPIC TRIGGERS FOR BONE AND CARTILAGE REPAIR (OPHIS)
Date du début: 1 sept. 2010, Date de fin: 31 août 2014,
Osteoarthritis (OA) and osteoporosis (OP) are disabling, degenerative bone diseases with significant economic and societal impacts. The incidence of these conditions increases with age but in recent years the number of younger patients has increased, due mainly to factors related to modern life-styles. The efficiency of current pharmacologic and implant-based solutions are limited and often poorly ...
Voir le projet
9
Participants partenaires
TERMINÉ
"Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy." (FIGHT-MG)
Date du début: 1 déc. 2009, Date de fin: 31 mai 2014,
"Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies. We will address the: 1. Natural course of disease: determine factors associated wi ...
Voir le projet
13
Participants partenaires
TERMINÉ
Pharmaceutical Medicine Training Programme (PHARMATRAIN)
Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet
52
Participants partenaires
TERMINÉ
Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)
Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,
"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet
39
Participants partenaires
TERMINÉ
Systems Biology of T-cell Activation in Health and Disease (SYBILLA)
Date du début: 1 avr. 2008, Date de fin: 30 sept. 2013,
T-cell activation, whether induced by pathogens or auto-antigens, is a complex process relying on multiple layers of tightly controlled intracellular signalling modules that form an intricate network. Defects in this network can cause severe and chronic disorders such as autoimmune diseases. Although 5% of the population suffer from these diseases, only a few therapeutic treatments are available. ...
Voir le projet
22
Participants partenaires
TERMINÉ
Training Multidisciplinary scientists for Tissue Engineering and Regenerative Medicine (MultiTERM)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
MultiTERM is a training network providing multidisciplinary training for 13 early stage scientists in 5 host institutes that will deliver a number of excellently trained, highly employable scientists for companies and academia in the field of tissue engineering and regenerative medicine (TERM). The aging population of the EU requires the development of new treatment strategies for diseased, defect ...
Voir le projet
5
Participants partenaires
TERMINÉ
Magnetic Scaffolds for in vivo Tissue Engineering (MAGISTER)
Date du début: 1 déc. 2008, Date de fin: 30 nov. 2012,
The main driving idea of the project is the creation of conceptually new type of scaffolds able to be manipulated in situ by means of magnetic forces. This approach is expected to generate scaffolds with such characteristics as multiple use and possibly multipurpose delivery in order to repair large bone defects and ostheocondral lesions in the articular surface of the skeletal system. The major ...
Voir le projet
21
Participants partenaires
TERMINÉ
Angiogenesis-inducing Bioactive and Bioresponsive Scaffolds in Tissue Enginering (AngioScaff)
Date du début: 1 déc. 2008, Date de fin: 30 nov. 2012,
Angiogenesis underlies almost all biological processes of morphogenesis, including those in tissue repair and regeneration. Physiological angiogenesis is controlled by a complex interplay between cells and their environment: the extracellular matrix (ECM) provides signaling via numerous ECM adhesion molecules and growth factors bound to ECM polysaccharide components; and cells locally degrade and ...
Voir le projet
33
Participants partenaires
TERMINÉ
European Network for Cell Imaging and Tracking Expertise (ENCITE)
Date du début: 1 juin 2008, Date de fin: 30 nov. 2012,
"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Voir le projet
30
Participants partenaires
TERMINÉ
Novel biofunctional high porous polymer scaffolds and techniques controlling angiogenesis for the regeneration and repair of the degenerated intervertebral disc (Disc Regeneration)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2012,
30% of European workers experience back pain, and it is the most frequently reported work-related disorder. The proposed work seeks to provide a cure for lower back pain by developing porous scaffolds and technology which will repair a damaged intervertebral disc (IVD) by enabling its regeneration to a natural healthy state or better. Injectable acellular and cell-loaded bioactive polymer-based sc ...
Voir le projet
17
Participants partenaires
TERMINÉ
Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host – Pathogen Interactions (CAREPNEUMO)
Date du début: 1 mars 2009, Date de fin: 29 févr. 2012,
"The diseases caused by Streptococcus pneumoniae are a major public health problem all over the world. Children, elderly people and immuno-compromised individuals are the high-risk targets for pneumococcal diseases. In spite of the availability of a large number of antibiotics the mortality and morbidity due to S. pneumoniae infections remain very high. There are two reasons for this: Firstly, the ...
Voir le projet
13
Participants partenaires
TERMINÉ
Targeting alpha-particle emitting radionuclides to combat cancer (TARCC)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting ...
Voir le projet